Support Center for Child Advocates’ Post

Lanier Law Firm founder Mark Lanier has been honored in the 2024 edition of Benchmark Litigation. Not only has Mark once again been named a Litigation Star, but he’s also recognized as one of the Top 100 Trial Lawyers in the country! Mark has spent years winning important verdicts in cases against drug manufacturers and the makers of medical devices, among others. Congratulations, Mark, on this honor! #lanierlawfirm #benchmarklitigation #litigation

Our Antitrust and Competition Litigation Practice Group has secured final approval of settlements worth tens of millions of dollars in two complex antitrust class actions. In October, Judge Alvin K. Hellerstein of the U.S. District Court for the Southern District of New York approved a $30 million settlement with drugmaker Novartis to resolve an antitrust case over a pay-for-delay agreement involving the high blood pressure drug Exforge, and Chief Judge Sheryl H. Lipman of the U.S. District Court for the Western District of Tennessee approved a settlement for $43.5 million and significant relief to unwind anticompetitive conduct in the All Star Cheer events market. “Our team has worked diligently for years to ensure that our clients and the other class members are properly compensated for the losses they suffered from the anticompetitive practices at the core of these cases,” says Partner Karin Garvey, who served as Co-Lead Counsel for the plaintiffs in the All Star Cheer litigation. “These outcomes not only hold corporations accountable for their anticompetitive behavior but also guard against such conduct in the future.” Read more about our cases: Novartis: https://lnkd.in/gs4yi6nA All Star Cheer: https://bit.ly/vbantitrust #Antitrust #ClassAction #Litigation

Today's spotlight features Miami Partner John J. Goran whose primary focus is on medical malpractice, pharmaceutical litigation, general liability, products liability, and assorted transportation cases. Learn more and contact him: https://bit.ly/3w61npL Through the years he has defended hospitals, physicians, assorted health care professionals, and insureds, including Fortune 500 companies. He has defended pharmacies throughout the state of Florida involving complex issues related to compounding and aseptic techniques. #MiamiLaw #Law #Lawyer #HallBoothSmith

On December 6, Patterson Belknap Partner Thomas Kurland will speak at American Conference Institute's 2023 Conference on Drug & Medical Device Litigation. Tom will join other industry experts for a breakout discussion titled “FDA in the Crosshairs: What Recent Court Activity and State Litigation Over Mifepristone Means for the Future of Agency Deference,” exploring the impact of the Supreme Court’s decision in Dobbs on the future of medical product liability cases. https://lnkd.in/eDBDEKrG

The FDCA and the Failure to Warn; Great construction of the FDCA and Preemption of State Law Claims: "Although '[a] simple conclusion that the harm to the plaintiff was foreseeable ... cannot by itself mandate a determination that a legal duty exists,' the other four factors that this court considers when making that determination, '(1) the normal expectations of the participants in the activity under review; (2) the public policy of encouraging participation in the activity, while weighing the safety of the participants; (3) the avoidance of increased litigation; and (4) the decisions of other jurisdictions,' also weigh in the plaintiff's favor ... With respect to the first factor, both users and manufacturers in this state would normally expect that the manufacturers would be required to take all reasonable steps to provide warnings about the known dangers of a product to the person or entity in the best position to take or recommend precautions, as expressly provided by § 52-572q. With respect to the second factor, public policy favors encouraging individuals to seek necessary medical treatment by ensuring that they can be confident that their healthcare providers have accurate, current and complete information about the risks of the medical devices that they are recommending to their patients and that, if manufacturers withhold information about inherently dangerous medical devices, patients can be compensated for foreseeable and preventable injuries caused by them. With respect to the third factor, litigation arising from a manufacturer's failure to warn users about the inherent dangers of its products is already a familiar feature of the Connecticut legal landscape. We cannot conclude that public policy mandates or counsels an exception for medical devices ... Finally, we conclude that the fourth factor—the decisions of other jurisdictions —weighs in favor of the plaintiff. Although the courts of other jurisdictions are split on this point, we find the cases cited by the plaintiff, in which federal and state courts have construed the product liability laws of our sister states as creating a duty to comply with federal law requiring manufacturers to report adverse events associated with inherently dangerous medical devices to the FDA, to be more persuasive than the cases cited by the defendants." From The 2nd Cir. Ct. App.'s Certified Question to the Conn. Supp. Ct. in Glover v. Bausch & Lomb, Inc. 275 A.3d 168 (Conn. 2022) #cartcelltherapy #cancerresearch #21cfr #cfr #fda #fdaapproval #fdaapproved #pharmaceutical #pharma #law #litigation #litigationsupport #regulatoryaffairs #regulatorycompliance #cmc #psychedelics #psychedelicscience #mentalhealth #mentalhealthawareness #clinicaltrials #clinicalresearch #cannabislaw #cannabis #cannabisindustry #cannabisnews #cannabisbusiness #mrna #mrnavaccines #geneediting #genetherapy #genetics (https://lnkd.in/guZXMFii)

Unveiling the 2023 ANDA Litigation Intelligence Report: Patexia leads in IP analytics with our latest milestone. Dive into dynamic Hatch-Waxman case trends, exploring pharmaceutical patent litigation like never before. 🔍 Insights into Shifting Dynamics: Over the years, ANDA litigation patterns shifted - from 29.3 cases/month in 2018 to 20.5 in 2020, surging to 21.9 and 24.8 in 2022 and 2023. This comprehensive report deciphers these trends, offering stats, terminated case outcomes, and rankings for attorneys, firms, and companies in brand, generic, and overall categories. 📌 Key Report Highlights: 1,428 ANDA cases in 5 years, involving 267 brand and 265 generic pharmaceuticals. 1,774 unique patents at the core. 226 law firms representing 469 entities. 1,666 ANDA attorneys leading the way. 270 attorneys as local counsel. Teva: 131 cases; MSN Labs: 100% success rate. 🗣️CEO's Perspective: Pedram Sameni, Patexia's CEO, highlights the report's role for pharma entities and practitioners navigating ANDA litigation. A groundbreaking addition - Patexia attorney reviews - presents top attorneys' perspectives. With advanced machine learning, our ranking methodology unveils the factors influencing success in ANDA litigation, aiding decision-makers. The 2023 ANDA Litigation Intelligence Report is available now, a must-have for legal professionals and stakeholders navigating the evolving realm of ANDA litigation. Get your copy at https://lnkd.in/dtMzqD74 https://lnkd.in/dG5jjWuz #ANDA #hatchwaxman#pharmaceutical #patent #fda 

👩⚖️ 👨⚕️ Expert witnesses in US drug and medical device litigation "In the United States, litigation over complex medical products universally requires expert testimony. The practical, procedural, and strategic aspects of expert discovery are among the most significant and nuanced issues in medical product litigation." Adrienne Busby and Eric Friedman of Faegre Drinker take a deep dive into the American practice relating to expert witnesses, with a focus on federal court practice alonside contextual comparisons to state and foreign jurisdictions. 🔗 https://lnkd.in/eJz_Cbqy #expertwitnesstestimony #medicaldevice #litigation

Creative legal strategies can lead to positive results in the face of challenging facts and seemingly long odds. Take a look at how Foley Hoag attorneys helped a biopharmaceutical client using an arbitration strategy to achieve success. #FoleyHoag

🔬 When dealing with pharmaceutical-related litigation, having a qualified expert witness can be instrumental in building a strong case. Learn how to find and work with these experts: https://lnkd.in/ef8GwPSw #expertwitness #litigation #law #insight

🔬 When dealing with pharmaceutical-related litigation, having a qualified expert witness can be instrumental in building a strong case. Learn how to find and work with these experts: https://lnkd.in/ef8GwPSw #expertwitness #litigation #law #insight